|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Manhattan Eye, Ear & Throat Hospital |
|---|---|
| Collaborator: |
Alcon Research |
| Information provided by: | Manhattan Eye, Ear & Throat Hospital |
| ClinicalTrials.gov Identifier: | NCT00211406 |
Purpose
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Retinopathy |
Drug: Anecortave Acetate Sterile Suspension (15 mg) |
Phase I |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, New York | |
| Manhattan Eye, Ear & Throat Hospital | |
| New York, New York, United States, 10021 | |
| Principal Investigator: | Lawrence Yannuzzi, MD | Manhattan Eye, Ear & Throat Hospital |
More Information
| ClinicalTrials.gov Identifier: | NCT00211406 History of Changes |
| Other Study ID Numbers: | Diabetic Retinopathy |
| Study First Received: | September 13, 2005 |
| Last Updated: | May 6, 2007 |
| Health Authority: | United States: Food and Drug Administration |
|
Diabetic Retinopathy Retinal Diseases Eye Diseases Diabetic Angiopathies Vascular Diseases |
Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases |